Peptron KRX:087010KOSDAQ
펩트론 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days8
DART filings, 7 days0
Articles tracked121since Sep 11
In Q2 2026, Peptron reported revenue of ₩1.4bn, up 1.4% year on year, and an operating loss of ₩7.9bn. Peptron (펩트론) appeared in 8 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 22 with 7 articles. The most common catalyst was contracts & orders (3). It was most often mentioned alongside Yuhan, ABL Bio and OliX Pharmaceuticals.
Filing signals 4 quarters of losses Screener
Peptron quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.4bn | +1.4% | −₩7.9bn | −₩7.7bn |
| Q1 2026 | ₩2.0bn | +21.4% | −₩5.8bn margin −293.8% | −₩6.1bn |
| Q4 2025 derived | ₩987m | -36.1% | −₩5.7bn | −₩4.7bn |
| Q3 2025 | ₩1.6bn | +172.3% | −₩6.2bn | −₩2.0bn |
| Q2 2025 | ₩1.4bn | +163.0% | −₩5.0bn | −₩3.8bn |
| Q1 2025 | ₩1.6bn | +239.5% | −₩4.4bn margin −268.6% | −₩3.3bn |
| Q4 2024 derived | ₩1.5bn | +93.2% | −₩3.5bn margin −227.4% | −₩5.0bn |
| Q3 2024 | ₩588m | -13.9% | −₩4.7bn | −₩4.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Peptron top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Peptron news Korean headlines
-
[빅데이터로본다] 생물공학 상장기업 2026년 10월 브랜드평판... 1위 알테오젠, 2위 펩트론, 3위 에이비엘바이오
1 more on this story · 1 outlets
- 생물공학 상장기업 2026년 10월 브랜드평판...알테오젠, 펩트론, 에이비엘바이오 順에너지신문 · Oct 28 10:36
-
펩트론 동물 반감기, 경쟁사는 더 길고·월 1회 인체 감량 근거 오리무중
1 more on this story · 1 outlets
- 펩트론 동물 반감기, 경쟁사는 더 길고·월 1회 인체 감량 근거 오리무중이데일리 · Oct 27 06:01
-
Major펩트론, 유한양행과 40억 기술이전 계약 해지…실제 수령액은 10억
1 more on this story · 1 outlets
- 펩트론, 유한양행과 40억 기술이전 계약 해지…실제 수령액은 10억조선일보 · Oct 22 15:23
-
임상 반려에 기술 이전 감감무소식…올릭스, 펩트론 쇼크에 롤러코스터 타는 바이오株
1 more on this story · 1 outlets
- 임상 반려에 기술 이전 감감무소식…올릭스, 펩트론 쇼크에 롤러코스터 타는 바이오株조선일보 · Oct 22 06:07
-
Exclusive월1회·최대 3개월 내세웠던 펩트론…특허 속 효능시험은 최대 2주 간격
1 more on this story · 1 outlets
- 월1회·최대 3개월 내세웠던 펩트론…특허 속 효능시험은 최대 2주 간격이데일리 · Oct 16 07:04